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Case-mix heterogeneity across studies complicates meta-analyses. As a result of this, 
treatments that are equally effective on patient subgroups may appear to have different 
effectiveness on patient populations with different case mix. It is therefore important 
that meta-analyses be explicit for what patient population they describe the treatment 
effect. To achieve this, we develop alternative approaches for meta-analysis of 
randomized clinical trials, which use individual patient data (IPD) from all trials to infer 
the treatment effect for the patient population in a given trial, based on direct 
standardization using either outcome regression (OCR) or inverse probability weighting 
(IPW). Accompanying random-effect meta-analysis models are developed. The new 
approaches enable disentangling heterogeneity due to case-mix inconsistency from that 
due to beyond case-mix reasons.  
Keywords: meta-analysis; causal inference; transportability; direct standardization; outcome 
regression; inverse probability weighting 
1. INTRODUCTION 
Meta-analysis (MA) is a cornerstone of comparative effectiveness research, as it allows 
synthesizing the evidence from multiple randomized controlled trials.
1–3
 One critical concern 
in meta-analysis is the presence of heterogeneity, which arises from the clinical and 
methodological diversity of the considered studies. For instance, different studies may differ 
in terms of the case-mix of participants, the version of the intervention that is provided, the 
outcome evaluation or as a result of potential biases.
4–9
 Random-effect meta-analyses are 
commonly employed to model such heterogeneity. Under a random-effects model, the 
treatment effects in the considered studies are supposed to have been sampled from a 
distribution of true effects. The summary estimate then represents the mean of that 
distribution,
2,10
 which can equivalently be viewed as the treatment effect in the study (and 
patient population) in which the random effect is zero. The case mix composition of such 
population is left implicit, apart from a high-level description via the eligibility criteria of the 
systematic review. 
In standard MA, much attention has been paid to diagnosing and preventing heterogeneity. To 
diagnose heterogeneity, several measures have been proposed to quantify how much observed 
effects (trial results) vary compared to what would be expected by chance only. Popular 
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measures are the tau-square, the variance of the random component in a random-effects 
model, or the I-square, which measures the proportion of total variation in study estimates that 
is due to heterogeneity.
2,11
 To prevent heterogeneity, it is commonly recommended that meta-
analyses be conducted only when studies are sufficiently homogeneous, usually based on the 
evaluation of Population, Intervention, Control and Outcome (PICO) components of 
studies.
1,2
 However, determining how much heterogeneity is acceptable is challenging. 
Indeed, even when the studies have enough in common to justify evidence synthesis, residual 
difference in terms of case-mix, among other factors, typically remain and may impact the 
summary result. Consider for instance a treatment that has a different effect in different 
subgroups of population, with the effect in any one subgroup being constant across different 
studies. Differences in case mix between studies will then give rise to apparent heterogeneity 
in the reported treatment effectiveness between studies, despite the causal effect of treatment 
being homogeneous. This heterogeneity may complicate the interpretation of the summary 
effect, in that it becomes unclear to what case mix it relates. It is therefore important that 
meta-analyses be explicit for what patient population they describe the treatment effect.  
In view of this, in this paper, we will propose individual patient data (IPD) techniques for 
meta-analyses of randomized controlled trials that infer the treatment effect for a population 
that is well-defined in terms of case mix. Building on recent work by Bareinboim and 
Pearl
6,12
, this is achieved by standardizing the results from the different trials to the same 
patient population, e.g. the patient population observed in one of the trials or any other 
population of interest, before meta-analyzing them as in a classical two-stage approach to IPD 
meta-analysis.
13,14
 As an added advantage, this enables one to decompose the overall 
heterogeneity between the trial results into two different sources: heterogeneity due to 
differences in case-mix between trials (called „case-mix heterogeneity‟) and heterogeneity due 
to other beyond case-mix reasons (called „beyond case-mix heterogeneity‟).  
We proceed as follows. In section 2, we propose two estimators which aim to standardize 
results of different trials over the case-mix of a target population. The subsequent meta-
analysis then infers the treatment effect in the given population by using the information 
standardized from other trials. We show in section 3 that under certain conditions, this 
approach not only gives valid results but allows for a more insightful assessment of 
heterogeneity in meta-analyses. The novel approach is illustrated by reanalyzing a published 
IPD meta-analysis evaluating the effect of vitamin D on the risk of respiratory infection in 
section 4. Some important challenges are then extensively discussed in the concluding section 
5. 
2. ALTERNATIVE APPROACHES FOR META-ANALYSIS OF RANDOMIZED 
CONTROLLED TRIALS: A CAUSAL FRAMEWORK 
2.1 Aim 
Our proposal below aims to infer the treatment effect for a well-defined population, e.g. the 
patient population observed in one (say, the largest or the most heterogeneous) of the 
considered trials. In particular, we will first use the data from each trial to infer the treatment 
effect for that considered patient population. That all of the obtained treatment effects relate to 
3 
 
the same patient population makes them easier to pool, which we will do next using standard 
meta-analysis techniques. By standardizing the results from the different trials to the same 
patient population before meta-analyzing them, we eliminate case-mix heterogeneity. Such 
heterogeneity arises when the treatment effect is modified by one or more of the factors used 
to define case-mix (on the scale of the considered treatment effect measure).  
Even when standardizing the results from all trials to one common patient population, 
heterogeneity may still be observed as different trials might focus on different doses, different 
routes of administration of a drug; or different variations of a non-pharmacological 
intervention for instance. Even when the same treatment is used across studies, the version of 
treatment will still likely be different due to other design-related aspects, e.g. because of 
differences in standard of care or patient management between studies, or because in one 
study there is a greater attempt to prevent noncompliance than in other studies. We will 
consider these as beyond case-mix heterogeneity. 
To formalize the problem, consider a meta-analysis of   RCTs to evaluate the comparative 
effectiveness of two treatments            on a dichotomous outcome           . Let   be 
an indicator of the study from which a given patient originates, which takes values from 1 to 
 . To make the beyond case mix difference between studies explicit, we will label the 
versions of treatment   as    to                for studies   to  , respectively. Besides, we 
denote       as the outcome that would be observed in a patient if this patient were assigned 
to the version of treatment     Each patient, therefore, will have    potentially observed 
outcomes. However, since each patient is only assigned to one specific version of treatment or 
control, only one of these outcomes can actually be observed for each patient. Due to this, the 
proposed outcomes         are often referred to as counterfactual outcomes. A more detailed 
discussion about the counterfactual outcome framework can be found elsewhere.
15,16
 
Let                        denote the chance of success if the patients in population 
  were given the version of treatment/control used in study  . Based on these probabilities, the 
effect of the treatment version   in population   can be expressed as a risk difference, relative 
risk or odds ratio. For instance, on the relative risk scale, we denote: 
        
              
              
   
which expresses the treatment effect when all individuals from population     were given 
the (version of) treatment versus control used in trial    Throughout, we will argue that the 
effects         for different        , but the same   are easier to pool, as the case-mix 
heterogeneity is cancelled out and all           describes the treatment effects for the same 
population  . 
3.2 Assumptions 
To identify         and the corresponding probabilities, the following assumptions are made: 
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(i) Ignorable study assignment6,12, which states that the trial indicator is independent of 
all counterfactual outcomes, conditioning on the prognostic factors  ; that is,        
    for         and              where       for random variable       means 
that   is conditionally independent of    given    This implies that individuals with 
the same characteristics   in different trials would have the same outcome risks if 
given the same treatments. This is satisfied when   contains all prognostic factors of 
the outcome that are differentially distributed between studies. This assumption cannot 
be tested in practice. However, it is partially testable when the control is the same in 
different studies, in the sense that                         , for then it 
should imply that          , which is testable. In practice, when there is 
evidence against the assumption that outcome is independent of trial indicator given 
    and  , one should first carefully verify the added assumption of common 
control (e.g. whether the control groups in different trials are really similar in terms of 
pharmacological properties or of associated risks of bias, etc.).  If this is indeed the 
case, then the considered set of covariates   is likely insufficient to define the case 
mix of the included studies. Such a limitation should be acknowledged. Note that 
traditional meta-analysis approaches are no less problematic when this assumption is 
violated. This is because summaries over studies that include very different case mix 
are prone to bias, as explained in the introduction, unless they involve an appropriate 
case-mix adjustment.  
(ii) Positivity17, which states that any individual with characteristics    in study     has 
a positive probability, based on these characteristics, of being included in study  :   
              This is similar to the notion of transitivity in network meta-
analysis.
18
 Violations of positivity may be deterministic or random.
17
 A deterministic 
violation occurs when the targeted populations of trials are relatively different, e.g. 
one study only includes children whereas the others recruit adults. In contrast, random 
violations of positivity may occur when there are trials of small sample size. In that 
case, it may happen by chance that no one in a given age class participates in one trial, 
even though the restrictions on age for eligibility are the same across trials. Besides, 
note that what is meant by positivity here is different from the conventional positivity 
assumption that appears in causal theory.
17
 The former basically assumes that     
     for patients in trial   is non-zero, which guarantees an adequate overlap between 
different trial populations in terms of case-mix. This is important to be able to learn 
about the treatment effect in the target population from what is observed in the 
original one. 
(iii) Consistency19, which states that       agrees with the observed outcome   for all 
individuals in study          who received treatment              . This is a 
plausible assumption in trials where interventions are effectively taking place.
20
 
(iv) Ignorable treatment assignment within study19, which states that within each trial, the 
treatment is independent of all counterfactual outcomes                        
This assumption is guaranteed to hold because of randomization within each 
individual trial.
21
 
3.3 Outcome regression approach 
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Under the aforementioned assumptions, it can be shown (Appendix 1) that: 
                                   ] 
  ∑                                 
Intuitively, this formula amounts to a simple recalibration (or reweighting) of the  -specific 
effects to account for the new  ‟s distribution.6 Assume that in population  , the outcome for 
each patient follows a logistic model:  
                                                                                    
where                          Under model (2), a straightforward estimator of 
               is obtained by using outcome regression: 
 ̂              
∑             ( ̂    ̂     ̂      ̂     ) 
∑         
 
As a result,         can be estimated as: 
  ̂      
∑             ( ̂    ̂    ̂      ̂    ) 
∑             ( ̂    ̂    ) 
 
where  ̂    ̂    ̂   and  ̂   are estimates obtained by fitting model (2) to the data from trial 
 . This strategy suffers from two drawbacks. First, the result of transporting the findings 
across studies may be heavily dependent upon the choice of model for the outcome, e.g., on 
the decision to include interactions of treatment with some baseline covariates. Second, this 
approach may induce inappropriate model extrapolations when patients in different studies 
have very different case mix
22
, as is likely the case in many meta-analyses. Such extrapolation 
is the result of making the outcome model fit well over the case-mix of study k, but then using 
it to make outcome predictions for the possibly different case-mix in study j. The severity of 
that extrapolation may easily go unnoticed in practice. 
3.4 Inverse probability weighting approach 
In view of the aforementioned concerns, we considered an alternative approach based on 
inverse probability weighting (IPW). IPW is a method commonly used to obtain marginal 
effects in observational studies, especially when there is time-dependent confounding.
23,24
 It 
can be shown (Appendix 2) that: 
               
 
      
 {                
        
        
 
 
          
} 
Assume further that for a given patient with the covariate profile  , the probability to be in 
trial   vs. in trial   follows a logistic propensity score model: 
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 This suggests estimating                as: 
 ̂              
∑ {                          ̂   ̂     
 
 ̂           
} 
∑         
 
where  ̂  and  ̂  are the estimates obtained by fitting model (3) to the data from trial   and  . 
This results in the following estimator for        : 
  ̂      
 
  
 
∑                   ̂   ̂      
∑                        ̂   ̂    
 
where    is the ratio between the number of treated vs. untreated patients in the trial    
Calculating this requires no modeling assumption about the outcome generating mechanism. 
Therefore, the estimator does not require a model for the outcome, which is important because 
inappropriate extrapolations could otherwise be made if the outcome model ignored certain 
forms of heterogeneity (e.g. covariate by study interactions). Instead, a propensity score 
model for          now must be correctly specified (e.g. by using multinomial regressions) 
to ensure that the estimator is unbiased in sufficiently large samples.
23–25
 
The IPW approach can be susceptible to the presence of unstable weights; that is, to some 
weights 
 ̂         
 ̂         
        ̂   ̂     being very large for some individuals.
24
 The estimation 
by IPW is then dominated by these large weights, which results in a huge reduction in 
effective sample size.
24,26
 In extreme cases, the IPW estimate for                can 
even exceed the theoretical boundary of 1. This can be remedied by noting that (see Appendix 
2):  
               
 {                
        
        
}
 {              
        
        
}
 
which suggests alternatively estimating         as: 
  ̂      
∑                   ̂   ̂     
∑                 ̂   ̂     
  
∑                        ̂   ̂    
∑                     ̂   ̂     
 
 
The additional denominators ensure weight stabilization, in the sense that they deliver weights 
between 0 and 1, thereby preventing the resulting stabilized IPW estimate for 
               from exceeding the boundary of 1.
24
 Extreme weights will often appear 
in settings where the different trials consider very different case-mix. They thus give the user 
a warning that it can be tricky to pool the results from such different trials, which could go 
unnoticed with the standard meta-analysis approach as well as with the outcome regression 
approach.  
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Other effect measures (such as risk difference and odds ratio) can also be defined and 
estimated in a similar way. The definition of the odds ratio         and its two 
corresponding estimators is given in Appendix 3.  
3.5 Deriving summary estimate and dismantling the two sources of heterogeneity 
To summarize the results   ̂      obtained from the same population     a random effect 
meta-analysis of the form: 
   (  ̂     )  (   (       )     
 ) 
   (       )  (   (      )    
 ) 
may now be performed. Here,        expresses the treatment effect for a clearly defined 
population, namely population  . It can be estimated via a weighted average of the log relative 
risks    (  ̂     ): 
   (  ̂    )  
∑       (  ̂     )
 
   
∑   
 
   
              
 
 ̂  
   ̂ 
 
This pooled estimate describes the summary treatment effect for the underlying population  . 
The standard error     of    (  ̂     ) can be estimated by either bootstrap or sandwich 
estimators. Further,   
  expresses how much results from different trials vary even when 
considered for the same patient population. This may result, for instance, from the differential 
effect of different treatment versions in the different trials. Importantly, since all estimates 
  ̂      focus on the same patient population (in terms of covariates L),   
  does not express 
heterogeneity due to differential case mix (in covariates L).  
An added advantage of the proposed framework is that, in view of the above, it results in a 
more informative way of assessing heterogeneity (see Figure 1). Indeed, since different 
          of the same population   are standardized over the same covariate distribution, 
these may only be heterogeneous due to beyond case-mix reasons across the different 
populations    . As a result, by testing the equality of          ,          for the same 
population j, one may develop insight in beyond case-mix heterogeneity. Similarly, when 
different                   differ for the same population    there is heterogeneity due to 
differential case mix among the populations.  
Comparison among different           can be done by using a Wald test. Consider for 
instance the null hypothesis                                which states that there 
is no beyond case mix heterogeneity. This can be rewritten in matrix form as         , 
where:  
   (                   )
 
;       (                         )  
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and  is an appropriately chosen            matrix. Under this null hypothesis, the test 
statistic:  
  (    ̂)
 
    ̂    ]  (    ̂)        
  
where  ̂ is the estimate of the covariance matrix of   ̂ . Here,  ̂  is derived by using 
conventional methods like bootstrap or sandwich estimators.
27
 
As a final remark, note that when all trials have the same control treatment, the assumption 
          naturally implies that beyond case-mix heterogeneity can be interpreted as 
treatment effectiveness heterogeneity. Indeed, suppose for instance that the outcome 
generating mechanism in population k obeys the logistic model: 
                                                            
from which we have                                 . The assumption that 
                                     
(or equivalently             then implies that                              
       for each    This holds if and only if           and          . The assumption 
         thus implies that all coefficients that are not related to the treatment must be 
constant over different studies. Beyond case-mix heterogeneity, if presents, is then due to 
differential treatment-related coefficients across populations. 
4. A SIMULATION STUDY 
4.1 Design 
We apply the proposed approaches in numerically simulated randomized controlled trials that 
evaluate a binary treatment     versus control with respect to a binary outcome    . We 
consider six settings. For pedagogic purposes, the first five settings investigate a relatively 
simple situation in which the meta-analysis only includes 2 trials, with a total of 1500 
patients. For these settings, the impact on   of treatment and of a continuous outcome 
predictor   in population           is generated using logistic models: 
                                                                                      
in line with the proposal of the previous section. The control group is assumed to be similar in 
the two trials, in the sense that             This implies that    and    are fixed across 
the trials. In contrast, the two coefficients     and     take on different values in different 
population  .  
The trial indicator   is generated using logistic regression in most of the simple settings (see 
table 1 for details). In setting 1, 3 and 5, the treatment is beneficial in one population and 
detrimental in the other on the marginal scale, although it is actually equally beneficial for 
those with the same value of the covariate   regardless of the study in which they were 
included. While all assumptions (section 3.2) are respected in setting 1, setting 3 and 5 assess 
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the behavior of the two estimators when the positivity assumption is nearly violated. In setting 
3, individuals with extreme values of   are nearly never recruited in the first trial. In setting 5, 
the targeted populations of the two trials are considerably different (table 1). 
In setting 2, the two sources of heterogeneity compensate each other and result in two 
(approximately) similar                   in two populations (table 1). In setting 4, the two 
populations have similar case mix but non-trivial beyond case-mix heterogeneity. 
We dedicate the final setting 6 to investigate the feasibility of the new approaches when the 
meta-analysis includes up to five different trials, with five baseline characteristics being 
differently distributed among these studies. These covariates are independently generated 
using normal distributions. The trial indicator   is generated using a multinomial regression 
(appendix 4). We also assume that the control group considers the same version of control 
treatment across five trials. The impact of treatment and of the baseline factors   on the 
outcome is generated using a logistic model that is identical across the five trials (appendix 4). 
In each run, 3000 patient profiles are generated. 
4.2 Analysis 
Bias – The new approach is assessed on both relative risk and odds ratio scales. Although the 
outcome obeys a logistic regression model, note that the use of relative risks is not 
problematic since we merely evaluate population relative risks. Across six settings, we 
investigate the bias of the two estimators when the outcome model (for OCR-based approach) 
and the propensity score model (for IPW-based approach) are correctly specified. In setting 1, 
the IPW-based estimator is further assessed when the propensity score model           
                     is misspecified, either by (i) not including the quadratic term    
or (ii) including neither the intercept nor the quadratic term     The OCR-based estimator is 
further assessed in setting 2, when the outcome models are misspecified by not including the 
treatment-covariate interaction term (table 1). In setting 5, a logistic model without the cubic 
term    is used for the OCR-based estimator that transfers the information from population 1 
towards population 2. In contrast, the outcome model is correctly specified when using OCR-
based estimator to transfer results of trial 2 towards trial 1 (table 1).  
In each setting, the true values     of all estimands, namely (i)                      
     (ii)         and (iii)         are derived as the average result across an independent 
5000-run simulation, which make use of the true regression coefficients. For instance, in 
setting 1 to 5, the true value for                          is calculated 
as 
 
    
∑  ̂ 
    
   , where 
 ̂  
∑                                   
    
   
∑        
 
The mean    ̅  of the corresponding DS/IPW-based estimator is computed over the main 
simulations. The bias and the relative bias are computed as    ̅           ̅      , 
respectively.  
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Variance estimation – The variance of the two proposed estimators for         and         
is derived using sandwich estimators.
27
 For comparison, bootstrap is also used for estimating 
the variance of the odds ratio estimators. For each simulation, 50 bootstrap samples are taken 
from the original dataset by sampling with replacement. We then compare the Monte Carlo 
variance of the OCR/IPW-based estimator and the mean of the estimated variance obtained 
via sandwich estimators or the bootstrap.  
Heterogeneity assessment – The new approach of heterogeneity assessment is also contrasted 
against the standard practice of simply testing the equality of the marginal effect measures 
          or          . The comparison of different relative risks or odds ratios is realized 
using Wald tests. 
4.3 Result 
4.3.1 Bias – The bias evaluation for settings 1 to 5 is presented in table 2 and 3. In setting 1, 
the two estimators have no bias when the model involved in each estimator is correctly 
specified. In contrast, the IPW-based estimator is biased when the propensity score model 
includes neither the intercept nor the quadratic term   . This is because the weight assignment 
under such a model is seriously distorted (appendix 5).  
In setting 2, the two estimators are unbiased when the involved models are correctly specified.  
However, when the essential interaction is not included in the outcome models, the OCR-
based estimator is seriously biased (table 2 and 3). 
In setting 3, the information from population 1 cannot be standardized over the case mix of 
population 2 via an IPW-based estimator (although the propensity score model is correctly 
specified). In fact, the IPW estimator is strongly driven by outcomes occurring in some 
patients with extremely large weights. This is most clearly seen in estimates of the 
probabilities                which in some simulations exceed the boundary of 1. This 
does not happen when standardizing the results of trial 2 over the case mix of population 1. 
Roughly speaking, to standardize the results of one study over the case mix of the other, we 
learn from subjects in different studies with similar characteristics. As individuals with 
extreme values of   present only in trial 2, there is no information about the effect of 
treatment assignment in trial 1 for these individuals. Such lack of information becomes 
apparent through the unstable behavior of the IPW estimator (table 2). If the weights are 
stabilized, IPW can behave better in the sense that it does not give any probability estimates 
outside the     ] interval. However, the weight-stabilized IPW estimates are still biased as the 
lack of information due to positivity violation remains (data not shown). While this is not 
problematic for the OCR estimate when the model is correctly specified, it does then rely on 
extreme extrapolation. 
In setting 4, the two estimators both give valid results as the involved models are correctly 
specified. In setting 5, the OCR-based estimator standardizing the results of trial 1 over the 
case mix of population 2 is biased (table 2 and 3). In fact, the model without the cubic term    
properly fits the data in trial 1. However, as there is little overlap between the two 
populations, using such a model for prediction in study 2 results in severe extrapolation 
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(appendix 5). The OCR approach simply ignores such concern and hence yields relatively 
severe bias. In contrast, as the outcome model is correctly specified when standardizing the 
information from trial 2 over the case mix of population 1, the OCR-based estimator has no 
bias. 
In setting 6, both OCR and IPW approaches give valid results when the model involved is 
correctly specified (data not shown). 
4.2.2 Estimator’s variance – Results of the two variance-estimating methods in setting 1 to 5 
are shown in table 4. Data are not shown for setting 6 because similar results were obtained. 
Compared to the OCR-based estimator, the IPW-based estimator has a larger variance. In 
every setting (except for setting 3), both sandwich and bootstrap variance estimators produce 
valid results. However, bootstrap estimates tend to give slightly larger standard errors. In 
setting 3, both methods fail to properly estimate the variance of the IPW estimator for 
        and         (table 5) because the aforementioned lack of overlap means that the 
data in this setting carry insufficient information that would allow for pooling the results. 
4.2.3 Heterogeneity assessment – As can be seen from table 5 and appendix 4, the proposed 
approach correctly specifies the source(s) of the total heterogeneity when the two estimators 
behave properly. The tests are more powerful when using the OCR-based estimator. In 
contrast, simply comparing           or           easily gives a misleading conclusion. For 
instance, in setting 2, the fact that there is no statistically significant difference between 
          or           might result in a misunderstanding that no heterogeneity presents. In 
setting 1, 3 and 5, by comparing           or           as is commonly done, one is unable 
to conclude the absence of beyond case-mix heterogeneity (table 5).  
In setting 1 and 2, the tests become inaccurate when the outcome model for the OCR-based 
approach or the propensity score model for the IPW-based approach are severely misspecified 
(setting 1 and 2). In setting 3, all tests involving         or         are biased when using 
the IPW-based estimator. These tests were not feasible in some cases because the IPW 
estimates of         were negative in some simulations (as the predicted probability 
 ̂              exceeded the boundary of 1) (table 5). This problem, however, can be 
partially resolved by using the weight-stabilized IPW estimate, in which case a positive value 
for         is guaranteed (table 6). Nonetheless, the stabilized   ̂      is still biased due to 
positivity violation. As a consequence, the related testing procedure continues to behave 
poorly. This may appear as a weakness, but in fact it merely signals the dangers of pooling the 
results from very different patient populations. 
In setting 4, the tests assessing heterogeneity due to differential case mix are seemingly too 
conservative. The Wald statistics in these tests are shrunken toward zero, which makes the 
Type I Error lower than the conventional level of 5% (table 5). The reason is that the two 
estimates   ̂      and   ̂      are strongly correlated under the null hypothesis of no 
heterogeneity due to differential case mix, which makes the variance of the difference 
   (  ̂     )     (  ̂     ) become extremely small. In such a situation, a slight bias in 
variance estimation can result in a considerable impact. More sophisticated methods for 
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variance estimation may then be indicated (appendix 6). This may however not be a major 
practical concern as we did not observe it in any other settings, in which the distributions of 
covariate   in the two populations are truly heterogeneous. 
In setting 5, all tests involving         or         give invalid results when using the OCR-
based estimator, as a result of serious bias. In setting 6, both approaches correctly specify the 
only source of heterogeneity, which is case-mix heterogeneity across the five trials (appendix 
4). 
In summary, both the OCR-based and IPW-based estimators are effective for case-mix 
standardization across different populations. The OCR-based estimator is optimal if the 
outcome model in each population is correctly specified. However, model misspecification is 
likely and difficult to diagnose when the different studies have very different case mix. 
Therefore, when using this estimator, it is best based on a flexible model that incorporates 
many possible treatment-covariate and covariate-covariate interactions, regardless of whether 
there is significant evidence for them. To lessen the risk of overfitting, the IPW approach 
seems more promising. First, it does not require modeling treatment-covariate interactions. 
Second, when the different trials in the meta-analysis are at least similar on the PICO basis, 
then positivity violations and thus extreme weights are less likely. Future frameworks should 
focus on improving the performance of this IPW approach. 
5. META-ANALYSIS OF THE EFFECT OF VITAMIN D SUPPLEMENTATION ON 
ACUTE RESPIRATORY TRACT INFECTION 
We apply the proposed approach to reanalyze a recently published IPD meta-analysis 
assessing the overall effect of vitamin D supplementation on the risk of experiencing at least 
one acute respiratory tract infection.
28
 Data for six eligible trials that include information on 6 
baseline covariates are available for analysis (appendix 7). For this illustration, we only 
consider the covariates that were collected across all trials. These are gender, age, BMI, 
influenza vaccination status and vitamin D concentration at baseline. All six trials adopt a 
randomization ratio of 1:1. One trial is a cluster randomized trial and one other has a 
relatively small sample size (i.e. 34 participants). We exclude the small trial and, for this 
illustration, ignore the potential clustering effect in the cluster randomized trial. The target 
population of one trial was moreover found to be very different from the others, i.e. it only 
includes male participants with 18 to 21 years of age (appendix 7). To prevent potential 
violations of positivity, this trial is excluded from the meta-analysis, leaving 4 trials. 
We apply the new IPW approach to meta-analyze the dataset on the log odds ratio scale. The 
main terms of all baseline covariates are included in the multinomial propensity score model. 
To decide on the inclusion of two-way interactions, we run two independent backward 
elimination processes, one for the logistic outcome model and the other for the multinomial 
propensity score model. Any interaction term that is included in one of the two final sets is 
considered for adjustment in the meta-analysis. This approach leads to the inclusion of five 
interaction terms, namely between sex and BMI, between sex and flu vaccination status, 
between age and gender, between age and influenza vaccination status, and between age and 
BMI.  
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For each IPW estimate, the weights are truncated by resetting the value of weights greater 
than the 95
th
 percentile to the value of the 95
th
 percentile. The presence of large weights after 
truncation (i.e. higher than 200) indicates a potential violation of the positivity assumption. If 
this is the case, we keep the corresponding IPW estimate in the meta-analysis to see its impact 
on the final summary. 
Results of the population-specific meta-analyses are given in figure 2 and appendix 8. The 
weight distributions after truncation are shown in appendix 9. As can be seen from these 
weights, there is a clear violation of positivity when transporting the result from trial 4 
(Martineau, 2015c) to trial 2 (Martineau, 2015a). This gets translated into a large standard 
error for the corresponding IPW estimate for         (appendix 9), whose impact on the final 
result is therefore dampened. 
The meta-analyses find no statistically significant treatment effect across different trial 
populations. However, vitamin D tends to be less effective than placebo in population 2 but 
the two treatments appear equally effective in the other populations, although these findings 
are not statistically significant (possibly due to the lack of power). Besides, there is no 
statistically significant evidence of heterogeneity, neither due to case-mix nor due to beyond 
case mix (appendix 8). 
6. DISCUSSION 
Assessing the impact of case-mix variation across the eligible studies is an important task in 
every meta-analysis. Case-mix heterogeneity, when it exists, can be quite a nuisance as it can 
make the result from a meta-analysis difficult to interpret. In this paper, we propose a novel 
framework which overcomes this by standardizing evidences across different evidence 
streams to one well-defined population before summarizing them. Simulation results 
demonstrate the adequacy of the new approach and indicate that such an approach allows for a 
more informative heterogeneity assessment. Dismantling case-mix heterogeneity from the 
total heterogeneity is especially meaningful since case-mix and beyond case-mix 
heterogeneity may sometimes compensate each other, thereby resulting in approximately 
equal marginal effect estimates (e.g. see setting 2 of the simulation study). In such cases, 
standard heterogeneity assessments like subgroup analysis and meta-regression are potentially 
misleading, as they are almost unable to detect the presence of both heterogeneity sources. 
Our proposal is readily extended to meta-analyses of observational studies. In the OCR 
approach, this merely requires that the outcome regression model additionally includes 
confounders of the treatment – outcome association. It is just slightly more involved in the 
IPW approach, where this would require additional weighting by the reciprocal of the 
probability of the observed treatment, given confounders. The resulting procedure for 
observational studies is arguably of even greater importance. Here, different studies typically 
adjust for different covariate sets, which may result in excess heterogeneity. Indeed, even if 
all studies evaluated the same study population and controlled for a sufficient set of 
confounders, typical effect measures (such as odds ratios and hazard ratios) would differ 
systematically between studies when some adjust for additional covariates and others do not. 
This is the result of non-collapsibility of these effect measures.
19,29–31
 It can make the 
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treatment effects from different observational studies difficult to pool. The proposed 
procedure overcomes this by standardizing the results from all studies to the same population.  
We did not discuss a number of important issues, such as the problem of covariates being 
systematically missing in some trials, or how to take into account the trials with limited 
sample size or with special study designs (e.g. clustered or non-inferiority trials). A relatively 
large sample size was also chosen in the simulation study, as the primary objective was to 
investigate the validity of the new meta-analysis and heterogeneity assessment approaches 
under reasonably good conditions in terms of power. The new approaches, therefore, should 
be further evaluated in a wider range of settings and of various sample sizes. Further, as 
individual patient data can be difficult to obtain in practice, it is important that the proposed 
approaches can be extended to aggregated data, so as to make it more data-friendly and more 
widely applicable.  
Finally, a drawback of the proposed approaches is that they require different random-effects 
meta-analyses, each targeted to the population of a different trial. This can easily be avoided, 
however, by instead standardizing the results to the population of only one of the trials  . 
From the viewpoint of generalizability, this is ideally the trial with the most heterogeneous 
case-mix. To avoid positivity violations, this is ideally the trial with the tightest case-mix. 
Alternatively, one may standardize the results to the population observed in an external 
reference electronic health registry. As noted by a referee, trialists may then consider mutual 
standardization in the original trial reports. In particular, each trial might then use inverse-
probability weighting to produce an effect measure estimate standardized to the case mix 
distribution in that reference register. Then meta-analysts could base a standard meta-analysis 
on these mutually standardized estimates, which would have the advantage of describing the 
effect for the same population. This would overcome the need for an IPD meta-analysis. As 
an added advantage, this may often lead to a reduction in between-trial heterogeneity. In 
practice, such an approach is also useful for supporting the decision making process. For 
instance, public health authorities in a given population might consider standardizing results 
of the different trials conducted elsewhere over the realistic case-mix encountered in their 
population. Results of the meta-analysis after this standardization will reflect more honestly 
the treatment effectiveness for such population structure, which is informative to decide 
whether or not the new intervention should be recommended in the interested population. 
While such a strategy contributes to increase the generalizability of the findings by directly 
addressing the issues of case mix, it does not take into account other types of non- 
generalizability, such as the one arising from differences between the real and anticipated trial 
interventions. To address this, the estimates           from trials   that come closest to being 
“pragmatic” are likely the ones that should receive more weight in the final meta-analysis. We 
will investigate this in future work. 
To summarize, we develop a novel meta-analysis approach for randomized clinical trials, 
which uses individual patient data from all trials to infer the treatment effect for the patient 
population in a given trial, either based on outcome regression or inverse probability 
weighting. We investigated the new approach via numerically simulated data and showed that 
the new approach can lead to insightful heterogeneity assessment in practice. Via reanalyzing 
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the real dataset of a published IPD meta-analysis, we also demonstrated that the new approach 
is feasible and applicable in practice. 
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Table 1 – Numerical set-up of the simulation study (setting 1 to 5) 
OCR1: outcome regression-based estimate using the correct outcome model; OCR2: the outcome model for the OCR estimate does not include the 
interaction term between   and  ; OCR3: a logistic model without the term    is used for the OCR-based estimate that transfers the information 
from population     toward population    , whereas the outcome model is correctly specified when transferring results of trial     toward 
trial    ;  IPW1: inverse probability weighting-based estimate using the correct PS model; IPW2: the PS model for the IPW estimate does not 
include L
2
; IPW3: the PS model for the IPW estimate includes neither the intercept nor   ; 
Setting Covariate distribution 
Linear predictor  
of the logistic outcome model 
Marginal RR Marginal OR Analysis 
1          
                               
                                    
             
             
             
OCR1, IPW1, 
IPW2, IPW3 
2          
                          
                                             
             
             
             
OCR1, OCR2,  
IPW1 
3                 
                                                       
             
             
             
             
OCR1, IPW1 
4                 
                                                 
             
             
             
             
OCR1, IPW1 
5                
                               
      
             
             
             
             
OCR3 
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Table 2 – Simulation results: bias assessment for the probabilities                
(*): probability                 RB: relative bias (%);  
Setting Approach 
*j = 1, k = 2, x = 1  *j = 1, k = 2, x = 0  *j = 2, k = 1, x = 1  *j = 2, k = 1, x = 0 
Bias RB  Bias RB  Bias RB  Bias RB 
1 OCR1 -0.0007 -0.1  0.0001 0.0  0.0005 0.1  -0.0007 -0.1 
 
IPW1 -0.0002 -0.0  0.0000 0.0  0.0004 0.1  0.0001 0.0 
 
IPW2 0.0040 0.8  -0.0002 -0.1  0.0004 0.1  -0.0089 -1.8 
 
IPW3 0.3614 70.8  0.2853 73.4  -0.1899 -41.7  -0.2120 -43.8 
  
           
2 OCR1 -0.0002 -0.0  -0.0005 -0.2  -0.0004 -0.1  -0.0004 -0.1 
 
OCR2 -0.0765 -15.2  0.0697 27.7  0.0643 22.9  -0.0735 -21.9 
 
IPW1 -0.0007 -0.1  0.0001 0.0  -0.0002 -0.1  0.0003 0.1 
  
           
3 OCR1 0.0007 0.1  -0.0003 -0.1  0.0031 0.5  0.0003 0.1 
 
IPW1 0.0005 0.1  0.0004 0.1  -0.0691 -12.0  -0.0719 -13.5 
  
           
4 OCR1 -0.0006 -0.1  -0.0005 -0.1  -0.0002 -0.1  0.0004 0.1 
 
IPW1 -0.0004 -0.1  0.0005 0.1  -0.0001 -0.0  -0.0002 -0.1 
    
 
  
 
  
 
  
5 OCR3 -0.0067 -1.0  -0.0081 -1.0  0.2379 59.8  0.1635 29.4 
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Table 3 – Simulation results: bias assessment (RR and OR estimates) 
RB: relative bias (%) 
Setting Approach 
                                   
Bias RB  Bias RB  Bias RB  Bias RB 
1 OCR1 0.0061 0.5  0.0028 0.3  0.0291 1.8  0.0172 1.9 
 
IPW1 0.0094 0.7  0.0090 1.0  0.0355 2.2  0.0304 3.4 
 
IPW2 0.0187 1.4  0.0273 2.9  0.0644 3.9  0.0616 6.9 
 
IPW3 -0.0132 -1.0  0.0474 5.0  3.0768 187.4  0.0982 11.0 
  
            
2 OCR1 0.0091 0.5  0.0068 0.8  0.0381 1.3  0.0160 2.1 
 
OCR2 -0.6643 -33.3  0.4908 58.6  -1.4175 -47.2  0.7371 95.2 
 
IPW1 0.0201 1.0  0.0149 1.8  0.0756 2.5  0.0264 3.4 
  
            
3 OCR1 -0.0002 -0.0  0.0130 1.2  0.0313 1.5  0.0658 5.6 
 
IPW1 0.0116 0.9  0.3622 33.6  0.1478 7.2  -0.0882 -7.5 
  
            
4 OCR1 0.0071 0.6  0.0019 0.2  0.0195 1.3  0.0108 1.4 
 
IPW1 0.0075 0.6  0.0064 0.8  0.0378 2.4  0.0118 1.5 
  
            
5 OCR3 -0.0040 -0.5  0.1242 17.3  0.0055 1.1  0.0240 4.5 
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Table 4 – Simulation results: variance estimation 
MCV: Monte Carlo variance; MEV:sandwich variance estimate; BTV: bootstrap variance estimate; (-) the variance is not estimable 
as the estimate   ̂      is negative in several simulations and cannot be transformed into log scale. This can be solved by using the 
stabilized IPW estimate (Appendix 3)  
Setting Approach 
                                                       
MCV MEV  MCV MEV  MCV MEV BTV  MCV MEV BTV 
1 OCR1 0.0063 0.0065  0.0095 0.0093  0.0220 0.0213 0.0210  0.0323 0.0327 0.0325 
 
IPW1 0.0116 0.0113  0.0207 0.0200  0.0383 0.0382 0.0381  0.0734 0.0724 0.0731 
 
IPW2 0.0115 0.0115  0.0194 0.0192  0.0393 0.0393 0.0387  0.0686 0.0678 0.0678 
 
IPW3 0.0110 0.0108  0.0190 0.0192  -  300.2 -  0.0352 0.0358 0.0353 
  
             
2 OCR1 0.0095 0.0095  0.0187 0.0184  0.0233 0.0233 0.0231  0.0387 0.0383 0.0389 
 
OCR2 0.0075 0.0073  0.0172 0.0172  0.0181 0.0185 0.0183  0.0345 0.0342 0.0342 
 
IPW1 0.0148 0.0145  0.0295 0.0293  0.0376 0.0384 0.0386  0.0635 0.0620 0.0615 
  
             
3 OCR1 0.0024 0.0024  0.0129 0.0127  0.0215 0.0213 0.0212  0.0666 0.0676 0.0677 
 
IPW1 0.0131 0.0133  0.3251 0.1346  0.1169 0.1185 0.1240  - 127.1 - 
  
             
4 OCR1 0.0069 0.0068  0.0094 0.0093  0.0211 0.0209 0.0208  0.0221 0.0223 0.0222 
 
IPW1 0.0125 0.0125  0.0157 0.0153  0.0399 0.0393 0.0389  0.0372 0.0365 0.0359 
  
             
5 OCR3 0.0054 0.0056  0.0236 0.0718  0.0243 0.0254 0.0252  0.0267 0.0682 0.0251 
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Table 5 – Simulation results: heterogeneity assessment (the percentage of simulations having a statistically significant result at a type I 
error risk of 5%). 
(*): using sandwich variance estimators; (1): using bootstrap variance estimators; (-) the test is not feasible as the estimate   ̂      is 
negative and cannot be transformed into log scale. This can be solved by using the stabilized IPW estimate (Table 7) 
 
Setting 1  Setting 2  Setting 3  Setting 4  Setting 5 
OCR1 IPW1 IPW2 IPW3  OCR1 OCR2 IPW1  OCR1 IPW1  OCR1 IPW1  OCR3 
New approach: 
Beyond case-
mix 
heterogeneity 
                5.1 5.3 5.6 5.1  75.3 4.9 59.0  4.6 5.3  89.3 68.0  6.0 
                4.8 5.7 5.2 5.7  82.9 4.7 62.2  5.6 15.1  89.2 67.9  42.3 
*                5.1 5.1 5.0 1.5  87.0 6.3 71.0  4.8 3.9  90.5 70.6  5.1 
*                5.2 4.8 5.0 5.9  86.2 6.3 66.8  4.7 -  90.6 70.5  5.0 
 
1                6.0 5.7 6.0 -  88.2 6.3 71.1  5.9 3.8  90.6 70.0  6.1 
 
1                5.8 5.6 6.1 6.7  87.5 6.3 67.1  5.8 -  90.8 70.0  6.6 
New approach: 
Case-mix 
heterogeneity 
                100 99.5 100 100  100 2.8 100  70.9 16.2  0.78 0.32  55.6 
                100 100 100 22.8  100 29.4 100  100 53.7  0.14 0.10  57.5 
*                100 99.1 100 100  100 0.0 100  83.4 -  0.56 0.22  52.2 
*                100 100 100 100  100 0.0 100  100 57.3  0.54 0.10  91.6 
 
1                100 99.1 99.9 100  100 0.0 99.9  83.7 -  0.78 0.42  39.9 
 
1                100 100 100 -  100 0.0 100  100 55.2  0.76 0.28  90.6 
Conventional 
approach 
                80.6 54.8 56.4 55.3  5.0 4.9 4.3  40.2 17.3  89.1 67.7  40.8 
*                81.4 54.4 54.9 55.6  5.3 6.3 5.9  51.2 17.1  90.7 70.4  7.4 
1                81.6 56.8 55.2 54.0  5.8 6.3 5.7  50.0 15.4  90.6 70.0  8.5 
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Table 6 – Simulation result: heterogeneity assessment in setting 3 (the percentage of simulations 
having a statistically significant result at a type I error risk of 5%), using the IPW-based estimator 
with stabilized weights (variance is derived by bootstrap) 
Heterogeneity Contrast 
IPW  
(weights stabilized) 
New approach: Beyond 
case-mix heterogeneity 
                5.3 
                11.8 
                5.4 
                15.6 
New approach: Case-
mix heterogeneity 
                12.8 
                88.7 
                16.9 
                94.1 
Conventional approach                 38.8 
                 46.5 
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Figure 1 – The proposal in a nutsell 
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Figure 2 – Data analysis: IPW approach 
 
